 Nanette Santoro
Concepts (953)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 104 | 2026 | 317 | 21.390 |
Why?
| | Hot Flashes | 40 | 2025 | 87 | 10.700 |
Why?
| | Infertility, Female | 47 | 2024 | 110 | 8.280 |
Why?
| | Estrogen Replacement Therapy | 35 | 2026 | 143 | 6.740 |
Why?
| | Menstrual Cycle | 40 | 2026 | 139 | 6.370 |
Why?
| | Women's Health | 44 | 2026 | 312 | 6.260 |
Why?
| | Perimenopause | 26 | 2025 | 64 | 6.250 |
Why?
| | Follicle Stimulating Hormone | 65 | 2026 | 247 | 5.780 |
Why?
| | Polycystic Ovary Syndrome | 36 | 2026 | 185 | 5.570 |
Why?
| | Estradiol | 61 | 2026 | 525 | 5.570 |
Why?
| | Luteinizing Hormone | 58 | 2026 | 187 | 5.380 |
Why?
| | Ovary | 28 | 2025 | 227 | 5.200 |
Why?
| | Endocrinology | 9 | 2023 | 77 | 4.490 |
Why?
| | Postmenopause | 37 | 2026 | 377 | 4.330 |
Why?
| | Metabolic Syndrome | 17 | 2026 | 354 | 3.880 |
Why?
| | Progesterone | 40 | 2026 | 258 | 3.730 |
Why?
| | Anti-Mullerian Hormone | 16 | 2023 | 58 | 3.700 |
Why?
| | Infertility | 13 | 2024 | 55 | 3.600 |
Why?
| | Reproductive Medicine | 8 | 2023 | 18 | 3.380 |
Why?
| | Live Birth | 23 | 2024 | 73 | 3.340 |
Why?
| | Estrogens | 26 | 2026 | 372 | 3.310 |
Why?
| | Female | 366 | 2026 | 77252 | 3.160 |
Why?
| | Receptors, Neurokinin-3 | 5 | 2025 | 8 | 2.810 |
Why?
| | Ovulation Induction | 30 | 2024 | 56 | 2.770 |
Why?
| | Obesity | 33 | 2024 | 3042 | 2.740 |
Why?
| | Fertility | 16 | 2024 | 166 | 2.720 |
Why?
| | Primary Ovarian Insufficiency | 14 | 2021 | 40 | 2.690 |
Why?
| | Fertilization in Vitro | 19 | 2024 | 87 | 2.580 |
Why?
| | Vasomotor System | 11 | 2025 | 47 | 2.530 |
Why?
| | Humans | 389 | 2026 | 143560 | 2.520 |
Why?
| | Hormones | 13 | 2021 | 138 | 2.470 |
Why?
| | Androgens | 15 | 2021 | 194 | 2.420 |
Why?
| | Diet, High-Fat | 3 | 2026 | 260 | 2.370 |
Why?
| | Luteal Phase | 16 | 2020 | 46 | 2.340 |
Why?
| | Reproduction | 9 | 2022 | 206 | 2.150 |
Why?
| | Aging | 30 | 2025 | 1946 | 2.120 |
Why?
| | Adult | 202 | 2026 | 40012 | 2.100 |
Why?
| | Gonadal Steroid Hormones | 15 | 2025 | 140 | 2.090 |
Why?
| | Heterocyclic Compounds, 2-Ring | 8 | 2024 | 19 | 2.040 |
Why?
| | Biomarkers | 37 | 2026 | 4241 | 2.020 |
Why?
| | Ovarian Follicle | 11 | 2025 | 72 | 1.900 |
Why?
| | Thiadiazoles | 8 | 2024 | 27 | 1.870 |
Why?
| | Estrogens, Conjugated (USP) | 15 | 2026 | 52 | 1.850 |
Why?
| | Cryopreservation | 6 | 2024 | 107 | 1.800 |
Why?
| | Endometrium | 15 | 2020 | 62 | 1.790 |
Why?
| | Pregnanediol | 13 | 2026 | 20 | 1.790 |
Why?
| | Depression | 13 | 2024 | 1512 | 1.740 |
Why?
| | Ovulation | 14 | 2018 | 40 | 1.740 |
Why?
| | Fertility Agents, Female | 14 | 2022 | 21 | 1.690 |
Why?
| | Testosterone | 24 | 2021 | 423 | 1.680 |
Why?
| | Menopause, Premature | 4 | 2021 | 12 | 1.670 |
Why?
| | Pregnancy | 73 | 2024 | 7153 | 1.620 |
Why?
| | Pregnancy Rate | 22 | 2024 | 68 | 1.600 |
Why?
| | Cardiovascular Diseases | 23 | 2024 | 2113 | 1.550 |
Why?
| | Hypothalamo-Hypophyseal System | 6 | 2024 | 198 | 1.520 |
Why?
| | Hormone Replacement Therapy | 9 | 2022 | 102 | 1.500 |
Why?
| | Sexual Dysfunction, Physiological | 9 | 2018 | 71 | 1.480 |
Why?
| | Double-Blind Method | 34 | 2025 | 2017 | 1.480 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2024 | 158 | 1.480 |
Why?
| | Longevity | 2 | 2025 | 175 | 1.430 |
Why?
| | Estrone | 12 | 2026 | 40 | 1.420 |
Why?
| | Infertility, Male | 11 | 2022 | 74 | 1.410 |
Why?
| | Quality of Life | 18 | 2024 | 3080 | 1.380 |
Why?
| | Middle Aged | 130 | 2026 | 35343 | 1.360 |
Why?
| | Carotid Intima-Media Thickness | 10 | 2021 | 68 | 1.360 |
Why?
| | Mental Health | 3 | 2024 | 770 | 1.360 |
Why?
| | Premenopause | 14 | 2022 | 120 | 1.300 |
Why?
| | Body Mass Index | 35 | 2026 | 2430 | 1.270 |
Why?
| | Amenorrhea | 12 | 2017 | 31 | 1.260 |
Why?
| | Gonadotropin-Releasing Hormone | 16 | 2022 | 213 | 1.240 |
Why?
| | Sleep Wake Disorders | 8 | 2026 | 315 | 1.230 |
Why?
| | Vagina | 3 | 2020 | 193 | 1.210 |
Why?
| | Vaginal Diseases | 3 | 2020 | 19 | 1.190 |
Why?
| | Hypothalamus | 10 | 2014 | 154 | 1.180 |
Why?
| | Endocrinologists | 3 | 2023 | 13 | 1.170 |
Why?
| | Hormone Antagonists | 2 | 2021 | 34 | 1.120 |
Why?
| | Pregnancy Outcome | 11 | 2024 | 464 | 1.120 |
Why?
| | Inhibins | 8 | 2018 | 42 | 1.100 |
Why?
| | Embryo Transfer | 10 | 2024 | 37 | 1.090 |
Why?
| | Gynecology | 2 | 2021 | 180 | 1.080 |
Why?
| | Atherosclerosis | 6 | 2024 | 406 | 1.050 |
Why?
| | Prospective Studies | 47 | 2025 | 7900 | 1.050 |
Why?
| | Endometriosis | 4 | 2022 | 57 | 1.020 |
Why?
| | Anovulation | 7 | 2015 | 8 | 1.020 |
Why?
| | Hyperlipidemias | 5 | 2022 | 127 | 1.010 |
Why?
| | Uterus | 4 | 2019 | 221 | 0.970 |
Why?
| | Randomized Controlled Trials as Topic | 20 | 2024 | 1672 | 0.950 |
Why?
| | Young Adult | 38 | 2026 | 13972 | 0.940 |
Why?
| | Treatment Outcome | 40 | 2024 | 11365 | 0.930 |
Why?
| | Hyperinsulinism | 3 | 2022 | 115 | 0.920 |
Why?
| | Clomiphene | 9 | 2021 | 15 | 0.920 |
Why?
| | Patient Selection | 7 | 2021 | 691 | 0.910 |
Why?
| | Sex Hormone-Binding Globulin | 15 | 2025 | 53 | 0.910 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 58 | 0.900 |
Why?
| | Insulin Resistance | 11 | 2025 | 1234 | 0.890 |
Why?
| | Insulin | 12 | 2025 | 2497 | 0.850 |
Why?
| | Preconception Care | 2 | 2024 | 50 | 0.850 |
Why?
| | Follicle Stimulating Hormone, Human | 3 | 2022 | 12 | 0.840 |
Why?
| | Fertility Preservation | 1 | 2024 | 53 | 0.840 |
Why?
| | Adipokines | 1 | 2024 | 53 | 0.840 |
Why?
| | United States | 52 | 2026 | 15554 | 0.830 |
Why?
| | Adipose Tissue | 4 | 2024 | 654 | 0.830 |
Why?
| | Salpingo-oophorectomy | 1 | 2024 | 18 | 0.830 |
Why?
| | Life Cycle Stages | 1 | 2023 | 39 | 0.820 |
Why?
| | Biomedical Research | 4 | 2023 | 699 | 0.810 |
Why?
| | HIV Infections | 17 | 2024 | 3013 | 0.810 |
Why?
| | Glucose Tolerance Test | 2 | 2024 | 368 | 0.800 |
Why?
| | Menarche | 2 | 2017 | 53 | 0.800 |
Why?
| | Hypogonadism | 9 | 2024 | 92 | 0.790 |
Why?
| | Longitudinal Studies | 26 | 2026 | 3006 | 0.790 |
Why?
| | Gonadotropins | 5 | 2020 | 40 | 0.790 |
Why?
| | Weight Loss | 6 | 2024 | 812 | 0.790 |
Why?
| | Aromatase | 3 | 2014 | 31 | 0.770 |
Why?
| | Progestins | 4 | 2017 | 85 | 0.760 |
Why?
| | Administration, Cutaneous | 13 | 2026 | 129 | 0.750 |
Why?
| | Irritable Mood | 3 | 2018 | 50 | 0.750 |
Why?
| | Drug Compounding | 3 | 2021 | 104 | 0.750 |
Why?
| | Ovarian Reserve | 3 | 2020 | 16 | 0.750 |
Why?
| | Body Composition | 11 | 2025 | 711 | 0.750 |
Why?
| | Corpus Luteum | 8 | 2017 | 20 | 0.740 |
Why?
| | Pituitary Gland | 6 | 2021 | 151 | 0.740 |
Why?
| | Leiomyoma | 5 | 2025 | 58 | 0.730 |
Why?
| | Sexual Health | 1 | 2023 | 68 | 0.720 |
Why?
| | Cytokines | 4 | 2024 | 2097 | 0.720 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2021 | 1413 | 0.710 |
Why?
| | Risk Factors | 49 | 2024 | 10644 | 0.700 |
Why?
| | Abortion, Spontaneous | 8 | 2024 | 117 | 0.690 |
Why?
| | Research Subjects | 1 | 2021 | 43 | 0.690 |
Why?
| | Fetal Research | 1 | 2021 | 3 | 0.690 |
Why?
| | Soybean Oil | 1 | 2021 | 15 | 0.690 |
Why?
| | Embryo, Mammalian | 1 | 2022 | 236 | 0.680 |
Why?
| | Federal Government | 1 | 2021 | 24 | 0.680 |
Why?
| | Lipids | 7 | 2023 | 704 | 0.680 |
Why?
| | Cohort Studies | 30 | 2024 | 5891 | 0.680 |
Why?
| | Age Factors | 22 | 2023 | 3328 | 0.680 |
Why?
| | Hydrocortisone | 4 | 2022 | 311 | 0.670 |
Why?
| | Hand Strength | 1 | 2021 | 136 | 0.660 |
Why?
| | Pregnancy Complications | 3 | 2024 | 590 | 0.660 |
Why?
| | Bicycling | 1 | 2021 | 122 | 0.660 |
Why?
| | Sleep Initiation and Maintenance Disorders | 4 | 2018 | 193 | 0.660 |
Why?
| | Symptom Assessment | 2 | 2021 | 133 | 0.650 |
Why?
| | Adolescent | 49 | 2024 | 22482 | 0.650 |
Why?
| | Adiposity | 5 | 2026 | 532 | 0.640 |
Why?
| | Premature Birth | 4 | 2024 | 375 | 0.640 |
Why?
| | Cross-Sectional Studies | 31 | 2026 | 5743 | 0.630 |
Why?
| | Ultrasonography | 6 | 2018 | 769 | 0.620 |
Why?
| | Reproductive Health | 3 | 2023 | 91 | 0.620 |
Why?
| | Feasibility Studies | 1 | 2024 | 1051 | 0.620 |
Why?
| | Phospholipids | 1 | 2021 | 212 | 0.610 |
Why?
| | Obstetrics | 1 | 2021 | 177 | 0.610 |
Why?
| | Practice Guidelines as Topic | 3 | 2016 | 1557 | 0.590 |
Why?
| | Spatial Memory | 1 | 2019 | 27 | 0.580 |
Why?
| | Hysterosalpingography | 1 | 2018 | 8 | 0.580 |
Why?
| | Cognition | 11 | 2026 | 1261 | 0.570 |
Why?
| | Sexuality | 1 | 2018 | 30 | 0.570 |
Why?
| | Hypothalamic Diseases | 3 | 2017 | 18 | 0.570 |
Why?
| | Sleep | 9 | 2021 | 889 | 0.570 |
Why?
| | Ovarian Hyperstimulation Syndrome | 3 | 2008 | 5 | 0.570 |
Why?
| | Liver | 4 | 2024 | 1864 | 0.570 |
Why?
| | Menstruation | 10 | 2024 | 43 | 0.560 |
Why?
| | Thyrotropin | 4 | 2024 | 116 | 0.550 |
Why?
| | Life Style | 10 | 2024 | 483 | 0.540 |
Why?
| | Chorionic Gonadotropin | 10 | 2024 | 78 | 0.540 |
Why?
| | Anxiety | 5 | 2024 | 1090 | 0.530 |
Why?
| | Phenotype | 5 | 2024 | 3211 | 0.530 |
Why?
| | Insemination, Artificial | 5 | 2022 | 11 | 0.530 |
Why?
| | Abortifacient Agents, Nonsteroidal | 3 | 2024 | 20 | 0.530 |
Why?
| | Methotrexate | 5 | 2024 | 256 | 0.510 |
Why?
| | Military Personnel | 1 | 2024 | 684 | 0.510 |
Why?
| | Hyperandrogenism | 5 | 2024 | 21 | 0.500 |
Why?
| | Watchful Waiting | 3 | 2024 | 88 | 0.500 |
Why?
| | Hypopituitarism | 2 | 2014 | 16 | 0.500 |
Why?
| | Health Surveys | 5 | 2011 | 512 | 0.500 |
Why?
| | Hysterectomy | 5 | 2023 | 139 | 0.490 |
Why?
| | Substance-Related Disorders | 6 | 2009 | 1113 | 0.490 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 291 | 0.490 |
Why?
| | Fetus | 1 | 2021 | 806 | 0.480 |
Why?
| | Pregnancy Trimester, First | 2 | 2019 | 136 | 0.480 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2016 | 32 | 0.480 |
Why?
| | Cumulus Cells | 2 | 2015 | 6 | 0.480 |
Why?
| | Levonorgestrel | 1 | 2015 | 36 | 0.470 |
Why?
| | Uterine Hemorrhage | 3 | 2021 | 38 | 0.460 |
Why?
| | Sweating | 4 | 2018 | 41 | 0.460 |
Why?
| | Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.460 |
Why?
| | Circadian Rhythm | 3 | 2017 | 513 | 0.450 |
Why?
| | Azoospermia | 1 | 2015 | 10 | 0.450 |
Why?
| | Overweight | 5 | 2014 | 598 | 0.450 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 566 | 0.430 |
Why?
| | Surveys and Questionnaires | 20 | 2022 | 6025 | 0.430 |
Why?
| | Pulsatile Flow | 3 | 2011 | 55 | 0.430 |
Why?
| | Time Factors | 21 | 2025 | 7032 | 0.430 |
Why?
| | Bone Density | 7 | 2011 | 503 | 0.430 |
Why?
| | Vulvodynia | 1 | 2014 | 2 | 0.430 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 110 | 0.430 |
Why?
| | Granulosa Cells | 4 | 2021 | 33 | 0.420 |
Why?
| | Nitriles | 5 | 2015 | 193 | 0.410 |
Why?
| | Triazoles | 5 | 2015 | 168 | 0.410 |
Why?
| | Blood Proteins | 1 | 2015 | 247 | 0.410 |
Why?
| | Obesity, Abdominal | 3 | 2026 | 46 | 0.390 |
Why?
| | Pregnancy, Multiple | 4 | 2015 | 18 | 0.390 |
Why?
| | Osteoporosis | 1 | 2016 | 244 | 0.390 |
Why?
| | Pregnancy, Ectopic | 4 | 2024 | 54 | 0.390 |
Why?
| | Cross-Over Studies | 4 | 2022 | 583 | 0.390 |
Why?
| | Solubility | 2 | 2023 | 239 | 0.380 |
Why?
| | Uterine Neoplasms | 3 | 2025 | 96 | 0.370 |
Why?
| | Parity | 2 | 2011 | 110 | 0.370 |
Why?
| | Prevalence | 14 | 2025 | 2830 | 0.370 |
Why?
| | Indoles | 1 | 2016 | 479 | 0.370 |
Why?
| | Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.370 |
Why?
| | Follicular Phase | 12 | 2014 | 39 | 0.370 |
Why?
| | Complementary Therapies | 3 | 2022 | 92 | 0.370 |
Why?
| | Male | 65 | 2024 | 71501 | 0.370 |
Why?
| | Follow-Up Studies | 17 | 2025 | 5308 | 0.360 |
Why?
| | Prolactin | 4 | 2022 | 92 | 0.360 |
Why?
| | Stress, Psychological | 8 | 2018 | 1134 | 0.360 |
Why?
| | Aged | 26 | 2026 | 25322 | 0.350 |
Why?
| | Human Growth Hormone | 2 | 2022 | 46 | 0.350 |
Why?
| | Cell Cycle | 1 | 2015 | 648 | 0.350 |
Why?
| | Intracranial Thrombosis | 1 | 2011 | 18 | 0.350 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 58 | 0.350 |
Why?
| | Fallopian Tubes | 3 | 2018 | 33 | 0.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2008 | 278 | 0.340 |
Why?
| | Endocrine System | 1 | 2011 | 21 | 0.340 |
Why?
| | Uterine Diseases | 2 | 2007 | 17 | 0.330 |
Why?
| | Weight Gain | 5 | 2020 | 550 | 0.330 |
Why?
| | Inflammation | 4 | 2024 | 2881 | 0.320 |
Why?
| | Coronary Artery Disease | 4 | 2019 | 722 | 0.320 |
Why?
| | Logistic Models | 14 | 2015 | 2107 | 0.310 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2021 | 43 | 0.310 |
Why?
| | Activins | 3 | 2005 | 29 | 0.310 |
Why?
| | Regression Analysis | 7 | 2020 | 1013 | 0.310 |
Why?
| | Prognosis | 15 | 2020 | 4152 | 0.310 |
Why?
| | Odds Ratio | 14 | 2015 | 1060 | 0.310 |
Why?
| | Oocyte Donation | 1 | 2009 | 4 | 0.300 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1089 | 0.300 |
Why?
| | Vulva | 1 | 2009 | 24 | 0.300 |
Why?
| | Exercise | 3 | 2022 | 2152 | 0.300 |
Why?
| | Trinucleotide Repeats | 1 | 2009 | 31 | 0.300 |
Why?
| | Incidence | 9 | 2025 | 2844 | 0.290 |
Why?
| | Multivariate Analysis | 13 | 2015 | 1510 | 0.290 |
Why?
| | Lactation | 2 | 2024 | 192 | 0.290 |
Why?
| | Fertility Agents | 2 | 2020 | 2 | 0.290 |
Why?
| | Luteal Cells | 1 | 2008 | 2 | 0.290 |
Why?
| | Semen | 4 | 2022 | 22 | 0.290 |
Why?
| | Administration, Oral | 8 | 2020 | 842 | 0.290 |
Why?
| | Multicenter Studies as Topic | 8 | 2022 | 389 | 0.290 |
Why?
| | Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.290 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 724 | 0.280 |
Why?
| | Signal Transduction | 3 | 2021 | 5214 | 0.280 |
Why?
| | Administration, Intravaginal | 2 | 2020 | 18 | 0.280 |
Why?
| | Ovariectomy | 3 | 2023 | 160 | 0.280 |
Why?
| | Carotid Artery Diseases | 2 | 2020 | 64 | 0.280 |
Why?
| | Bone Remodeling | 2 | 2008 | 77 | 0.280 |
Why?
| | Vitamin D Deficiency | 2 | 2021 | 188 | 0.280 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 64 | 0.280 |
Why?
| | Mentors | 1 | 2010 | 215 | 0.270 |
Why?
| | Mood Disorders | 3 | 2015 | 139 | 0.270 |
Why?
| | Oocyte Retrieval | 3 | 2015 | 12 | 0.270 |
Why?
| | Breast Neoplasms | 4 | 2022 | 2318 | 0.270 |
Why?
| | Polyps | 1 | 2007 | 13 | 0.270 |
Why?
| | Metformin | 3 | 2012 | 331 | 0.270 |
Why?
| | Adaptation, Psychological | 3 | 2018 | 686 | 0.270 |
Why?
| | Risk Assessment | 12 | 2024 | 3577 | 0.260 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2023 | 266 | 0.260 |
Why?
| | Pericardium | 3 | 2019 | 61 | 0.260 |
Why?
| | Virilism | 1 | 2007 | 7 | 0.260 |
Why?
| | Vitamin D | 3 | 2021 | 401 | 0.260 |
Why?
| | Models, Biological | 6 | 2025 | 1831 | 0.260 |
Why?
| | Antioxidants | 2 | 2021 | 594 | 0.250 |
Why?
| | Dehydroepiandrosterone Sulfate | 6 | 2011 | 42 | 0.250 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 165 | 0.250 |
Why?
| | Fertilization | 3 | 2022 | 44 | 0.250 |
Why?
| | Reproductive Techniques | 3 | 2001 | 5 | 0.250 |
Why?
| | Attitude to Health | 3 | 2009 | 451 | 0.240 |
Why?
| | Child | 24 | 2024 | 22725 | 0.240 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2022 | 318 | 0.240 |
Why?
| | Affect | 3 | 2018 | 315 | 0.240 |
Why?
| | Specimen Handling | 3 | 2018 | 181 | 0.240 |
Why?
| | Autoimmunity | 2 | 2024 | 927 | 0.240 |
Why?
| | Metabolome | 1 | 2009 | 374 | 0.240 |
Why?
| | Reference Values | 9 | 2020 | 811 | 0.230 |
Why?
| | Glucose | 3 | 2024 | 1042 | 0.230 |
Why?
| | New York City | 6 | 2010 | 90 | 0.230 |
Why?
| | Leuprolide | 4 | 1998 | 21 | 0.230 |
Why?
| | Pilot Projects | 5 | 2020 | 1838 | 0.230 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 363 | 0.230 |
Why?
| | Atrophy | 2 | 2020 | 197 | 0.220 |
Why?
| | Infant, Newborn | 10 | 2024 | 6366 | 0.220 |
Why?
| | Contraceptive Agents, Female | 2 | 2016 | 79 | 0.220 |
Why?
| | Dehydroepiandrosterone | 5 | 2016 | 51 | 0.220 |
Why?
| | Bariatric Surgery | 1 | 2008 | 233 | 0.220 |
Why?
| | Recovery of Function | 2 | 2008 | 703 | 0.220 |
Why?
| | Case-Control Studies | 7 | 2020 | 3625 | 0.220 |
Why?
| | Follistatin | 1 | 2004 | 12 | 0.220 |
Why?
| | Biology | 2 | 2023 | 92 | 0.220 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2024 | 7 | 0.220 |
Why?
| | Lipolysis | 1 | 2024 | 46 | 0.220 |
Why?
| | C-Reactive Protein | 4 | 2022 | 418 | 0.220 |
Why?
| | Ideal Body Weight | 1 | 2024 | 4 | 0.220 |
Why?
| | Vascular Calcification | 2 | 2019 | 112 | 0.220 |
Why?
| | Age of Onset | 3 | 2017 | 548 | 0.220 |
Why?
| | Oxidative Stress | 2 | 2021 | 1370 | 0.210 |
Why?
| | Thyroid Gland | 1 | 2024 | 93 | 0.210 |
Why?
| | Socioeconomic Factors | 7 | 2013 | 1324 | 0.210 |
Why?
| | Ovum | 1 | 2024 | 31 | 0.210 |
Why?
| | Physical Conditioning, Human | 1 | 2024 | 40 | 0.210 |
Why?
| | Embryo Culture Techniques | 1 | 2024 | 11 | 0.210 |
Why?
| | Alanine Transaminase | 1 | 2024 | 154 | 0.210 |
Why?
| | Academic Medical Centers | 4 | 2021 | 535 | 0.210 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3832 | 0.210 |
Why?
| | Diet, Fat-Restricted | 1 | 2024 | 77 | 0.210 |
Why?
| | Skin Aging | 2 | 2016 | 20 | 0.210 |
Why?
| | Pediatric Obesity | 2 | 2024 | 634 | 0.210 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 113 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 4 | 2026 | 3798 | 0.200 |
Why?
| | Focus Groups | 2 | 2024 | 570 | 0.200 |
Why?
| | Blood Glucose | 7 | 2025 | 2316 | 0.200 |
Why?
| | Neoplasms | 4 | 2024 | 2804 | 0.200 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1043 | 0.200 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 732 | 0.200 |
Why?
| | Endometrial Hyperplasia | 1 | 2023 | 7 | 0.200 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 235 | 0.200 |
Why?
| | Oligomenorrhea | 2 | 2014 | 8 | 0.200 |
Why?
| | Glucose Intolerance | 1 | 2024 | 146 | 0.200 |
Why?
| | Fractures, Bone | 2 | 2008 | 413 | 0.200 |
Why?
| | Bone Resorption | 2 | 2015 | 85 | 0.200 |
Why?
| | Drug Therapy, Combination | 5 | 2018 | 1058 | 0.200 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 8 | 0.200 |
Why?
| | Dyspareunia | 2 | 2016 | 8 | 0.200 |
Why?
| | Ovulation Detection | 1 | 2002 | 1 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 146 | 0.190 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 651 | 0.190 |
Why?
| | Carotid Stenosis | 1 | 2024 | 99 | 0.190 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 2 | 2019 | 25 | 0.190 |
Why?
| | Dilatation and Curettage | 2 | 2021 | 11 | 0.190 |
Why?
| | Interleukin-6 | 2 | 2022 | 781 | 0.190 |
Why?
| | Asymptomatic Diseases | 3 | 2018 | 98 | 0.190 |
Why?
| | Animals | 15 | 2024 | 38010 | 0.180 |
Why?
| | Retrospective Studies | 14 | 2024 | 16740 | 0.180 |
Why?
| | Simvastatin | 1 | 2002 | 62 | 0.180 |
Why?
| | Cuba | 3 | 2010 | 12 | 0.180 |
Why?
| | Reimbursement Mechanisms | 2 | 2001 | 82 | 0.180 |
Why?
| | Central America | 3 | 2010 | 24 | 0.180 |
Why?
| | Puerto Rico | 3 | 2010 | 54 | 0.180 |
Why?
| | South America | 3 | 2010 | 56 | 0.180 |
Why?
| | Fatty Liver | 1 | 2024 | 249 | 0.180 |
Why?
| | Goals | 1 | 2023 | 182 | 0.180 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 81 | 0.180 |
Why?
| | Blood Pressure | 4 | 2025 | 1755 | 0.180 |
Why?
| | Smoking | 6 | 2015 | 1580 | 0.180 |
Why?
| | Germ Cells | 1 | 2022 | 64 | 0.180 |
Why?
| | Washington | 1 | 2022 | 162 | 0.180 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 37 | 0.180 |
Why?
| | Anti-HIV Agents | 2 | 2005 | 861 | 0.170 |
Why?
| | Semen Analysis | 4 | 2022 | 14 | 0.170 |
Why?
| | Referral and Consultation | 3 | 2016 | 828 | 0.170 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 32 | 0.170 |
Why?
| | Health Behavior | 1 | 2007 | 790 | 0.170 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 32 | 0.170 |
Why?
| | Inflammation Mediators | 1 | 2024 | 510 | 0.170 |
Why?
| | Emulsions | 1 | 2021 | 57 | 0.170 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.170 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 621 | 0.170 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 257 | 0.170 |
Why?
| | Linear Models | 7 | 2019 | 858 | 0.170 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 245 | 0.170 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 196 | 0.160 |
Why?
| | Sexual Behavior | 3 | 2016 | 498 | 0.160 |
Why?
| | Thinness | 1 | 2021 | 98 | 0.160 |
Why?
| | Genetic Fitness | 1 | 2021 | 59 | 0.160 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 198 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 462 | 0.160 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 140 | 0.160 |
Why?
| | Dominican Republic | 2 | 2010 | 26 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2009 | 2542 | 0.160 |
Why?
| | Drug Combinations | 3 | 2016 | 372 | 0.160 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 124 | 0.160 |
Why?
| | Coitus | 2 | 2022 | 23 | 0.160 |
Why?
| | Vitamins | 1 | 2021 | 181 | 0.160 |
Why?
| | Spermatozoa | 3 | 2022 | 105 | 0.160 |
Why?
| | Lipoproteins, HDL | 3 | 2015 | 78 | 0.160 |
Why?
| | Electronics | 1 | 2000 | 74 | 0.160 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1282 | 0.160 |
Why?
| | Choice Behavior | 1 | 2021 | 173 | 0.160 |
Why?
| | Down-Regulation | 5 | 2019 | 644 | 0.160 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 186 | 0.150 |
Why?
| | Hypertension | 2 | 2024 | 1260 | 0.150 |
Why?
| | Ethics, Medical | 1 | 2000 | 83 | 0.150 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2011 | 42 | 0.150 |
Why?
| | Growth Hormone | 2 | 2022 | 99 | 0.150 |
Why?
| | Gene Expression | 3 | 2021 | 1505 | 0.150 |
Why?
| | RNA, Messenger | 6 | 2011 | 2852 | 0.150 |
Why?
| | Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.150 |
Why?
| | Puberty | 2 | 2019 | 158 | 0.150 |
Why?
| | Leptin | 3 | 2022 | 239 | 0.150 |
Why?
| | Acculturation | 2 | 2010 | 53 | 0.150 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 204 | 0.150 |
Why?
| | Erectile Dysfunction | 1 | 2019 | 39 | 0.150 |
Why?
| | Cell Nucleolus | 2 | 2010 | 19 | 0.150 |
Why?
| | Sulfonamides | 1 | 2023 | 582 | 0.150 |
Why?
| | Decidua | 1 | 2019 | 24 | 0.150 |
Why?
| | Adiponectin | 3 | 2022 | 244 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 894 | 0.150 |
Why?
| | Sperm Count | 4 | 2022 | 21 | 0.150 |
Why?
| | Spermatogenesis | 1 | 2019 | 88 | 0.150 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.140 |
Why?
| | Carotid Arteries | 1 | 2020 | 202 | 0.140 |
Why?
| | Surgeons | 1 | 2023 | 336 | 0.140 |
Why?
| | Ovarian Diseases | 3 | 1993 | 13 | 0.140 |
Why?
| | Allostasis | 1 | 2018 | 18 | 0.140 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 42 | 0.140 |
Why?
| | Waist Circumference | 5 | 2022 | 137 | 0.140 |
Why?
| | Adrenal Glands | 1 | 1998 | 79 | 0.140 |
Why?
| | Feeding Behavior | 1 | 2024 | 688 | 0.140 |
Why?
| | Genitalia | 1 | 2018 | 34 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 450 | 0.140 |
Why?
| | Periodicity | 8 | 2016 | 56 | 0.140 |
Why?
| | Placebos | 2 | 2015 | 195 | 0.140 |
Why?
| | Child Behavior | 1 | 2020 | 252 | 0.130 |
Why?
| | Decision Support Techniques | 1 | 2022 | 438 | 0.130 |
Why?
| | Keratin-18 | 1 | 2017 | 12 | 0.130 |
Why?
| | Religion | 1 | 2018 | 68 | 0.130 |
Why?
| | Precision Medicine | 1 | 2022 | 444 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 763 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 82 | 0.130 |
Why?
| | Brachial Artery | 1 | 2018 | 209 | 0.130 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2017 | 32 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 279 | 0.130 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 29 | 0.130 |
Why?
| | Comorbidity | 5 | 2014 | 1678 | 0.130 |
Why?
| | Receptors, Leptin | 2 | 2013 | 25 | 0.120 |
Why?
| | Body Weight | 4 | 2015 | 1003 | 0.120 |
Why?
| | Vaginal Creams, Foams, and Jellies | 1 | 2016 | 4 | 0.120 |
Why?
| | Orgasm | 1 | 2016 | 6 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2018 | 504 | 0.120 |
Why?
| | Oxytocics | 1 | 2016 | 15 | 0.120 |
Why?
| | Heart | 1 | 2020 | 632 | 0.120 |
Why?
| | Disease Progression | 4 | 2020 | 2856 | 0.120 |
Why?
| | Societies, Scientific | 1 | 2016 | 50 | 0.120 |
Why?
| | Antidepressive Agents | 1 | 2018 | 243 | 0.120 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 231 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 759 | 0.120 |
Why?
| | Endocrine System Diseases | 1 | 2016 | 35 | 0.120 |
Why?
| | Autoantibodies | 2 | 2024 | 1492 | 0.120 |
Why?
| | Fluoroimmunoassay | 2 | 1999 | 3 | 0.120 |
Why?
| | Confidence Intervals | 4 | 2011 | 332 | 0.120 |
Why?
| | Causality | 2 | 2014 | 132 | 0.120 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 169 | 0.120 |
Why?
| | Health Status | 3 | 2023 | 824 | 0.120 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2195 | 0.120 |
Why?
| | Oxytocin | 1 | 2016 | 51 | 0.120 |
Why?
| | Hirsutism | 2 | 2017 | 12 | 0.120 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2015 | 27 | 0.120 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 51 | 0.120 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 127 | 0.110 |
Why?
| | Mutation | 4 | 2013 | 4053 | 0.110 |
Why?
| | Body Constitution | 3 | 2004 | 54 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2015 | 63 | 0.110 |
Why?
| | Conserved Sequence | 1 | 1996 | 242 | 0.110 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 453 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1794 | 0.110 |
Why?
| | Sequence Alignment | 1 | 1996 | 367 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1452 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.110 |
Why?
| | Drug Approval | 1 | 2015 | 89 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2018 | 453 | 0.110 |
Why?
| | Fetal Growth Retardation | 2 | 2019 | 588 | 0.110 |
Why?
| | Child Development | 1 | 2020 | 506 | 0.110 |
Why?
| | Vasodilation | 1 | 2018 | 515 | 0.110 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 65 | 0.110 |
Why?
| | Societies, Medical | 3 | 2017 | 873 | 0.110 |
Why?
| | Infant | 15 | 2024 | 9981 | 0.110 |
Why?
| | Antibodies, Bacterial | 1 | 2015 | 146 | 0.110 |
Why?
| | Limit of Detection | 1 | 2015 | 95 | 0.110 |
Why?
| | Interferon-alpha | 1 | 1996 | 197 | 0.110 |
Why?
| | Survival Analysis | 4 | 2014 | 1332 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 86 | 0.110 |
Why?
| | Algorithms | 4 | 2011 | 1813 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 202 | 0.110 |
Why?
| | Chlamydia Infections | 1 | 2015 | 82 | 0.110 |
Why?
| | Migraine Disorders | 1 | 2016 | 113 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 571 | 0.110 |
Why?
| | Self Report | 4 | 2026 | 878 | 0.110 |
Why?
| | Physical Fitness | 1 | 2015 | 207 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1827 | 0.110 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 92 | 0.110 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 325 | 0.110 |
Why?
| | Core Binding Factors | 1 | 2013 | 2 | 0.100 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 21 | 0.100 |
Why?
| | Immunoglobulin G | 2 | 2015 | 898 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 346 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1226 | 0.100 |
Why?
| | Sperm Motility | 3 | 2022 | 35 | 0.100 |
Why?
| | Laparoscopy | 1 | 2018 | 474 | 0.100 |
Why?
| | Creatinine | 3 | 2022 | 494 | 0.100 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2086 | 0.100 |
Why?
| | Oocytes | 2 | 2011 | 178 | 0.100 |
Why?
| | Brain | 1 | 2026 | 2892 | 0.100 |
Why?
| | Bone Marrow Transplantation | 4 | 1999 | 292 | 0.100 |
Why?
| | Air Pollution | 1 | 2017 | 330 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 349 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2015 | 526 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2013 | 72 | 0.100 |
Why?
| | Range of Motion, Articular | 1 | 2015 | 415 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2021 | 1163 | 0.100 |
Why?
| | Child, Preschool | 16 | 2020 | 11737 | 0.100 |
Why?
| | Muscle Strength | 1 | 2015 | 333 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2015 | 8072 | 0.090 |
Why?
| | Nerve Tissue Proteins | 3 | 2011 | 607 | 0.090 |
Why?
| | Contraceptives, Oral | 2 | 2003 | 38 | 0.090 |
Why?
| | Chi-Square Distribution | 4 | 2015 | 527 | 0.090 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.090 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 773 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2015 | 371 | 0.090 |
Why?
| | Methadone | 2 | 2011 | 110 | 0.090 |
Why?
| | Rats | 3 | 2019 | 5610 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 340 | 0.090 |
Why?
| | Varicocele | 1 | 2011 | 10 | 0.090 |
Why?
| | China | 4 | 2011 | 226 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 844 | 0.090 |
Why?
| | Placenta Diseases | 1 | 2011 | 19 | 0.090 |
Why?
| | Tissue Banks | 1 | 2011 | 17 | 0.090 |
Why?
| | Receptors, Somatomedin | 1 | 2011 | 5 | 0.090 |
Why?
| | Receptors, Glucagon | 1 | 2011 | 26 | 0.090 |
Why?
| | Somatomedins | 1 | 2011 | 28 | 0.090 |
Why?
| | Epithelial Cells | 2 | 2009 | 1125 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2015 | 586 | 0.090 |
Why?
| | Receptor, trkA | 1 | 2011 | 15 | 0.090 |
Why?
| | Siblings | 2 | 2009 | 217 | 0.090 |
Why?
| | Narcotics | 1 | 2011 | 55 | 0.090 |
Why?
| | Skin | 1 | 2016 | 774 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2621 | 0.090 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1263 | 0.090 |
Why?
| | Glucagon | 1 | 2011 | 111 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 104 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 3 | 2006 | 274 | 0.080 |
Why?
| | Skin Physiological Phenomena | 1 | 2010 | 25 | 0.080 |
Why?
| | Pelvic Organ Prolapse | 1 | 2011 | 59 | 0.080 |
Why?
| | Actigraphy | 3 | 2017 | 126 | 0.080 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2010 | 11 | 0.080 |
Why?
| | Superovulation | 3 | 2012 | 8 | 0.080 |
Why?
| | Hip Fractures | 1 | 2011 | 85 | 0.080 |
Why?
| | Japan | 3 | 2011 | 135 | 0.080 |
Why?
| | Waist-Hip Ratio | 2 | 2026 | 37 | 0.080 |
Why?
| | Decision Trees | 1 | 2010 | 81 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 1997 | 1511 | 0.080 |
Why?
| | Fetal Diseases | 1 | 2011 | 182 | 0.080 |
Why?
| | Environment | 2 | 2003 | 343 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 389 | 0.080 |
Why?
| | Career Mobility | 1 | 2010 | 70 | 0.080 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 39 | 0.080 |
Why?
| | Lithium Chloride | 1 | 2009 | 12 | 0.080 |
Why?
| | Glucocorticoids | 1 | 1993 | 537 | 0.080 |
Why?
| | Quality Control | 2 | 2000 | 160 | 0.080 |
Why?
| | HIV Seropositivity | 2 | 2011 | 119 | 0.070 |
Why?
| | Blastocyst | 1 | 2009 | 48 | 0.070 |
Why?
| | Health Promotion | 1 | 2015 | 765 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 251 | 0.070 |
Why?
| | Comprehension | 1 | 2011 | 183 | 0.070 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 16 | 0.070 |
Why?
| | Memory | 1 | 2011 | 266 | 0.070 |
Why?
| | Proteomics | 1 | 2015 | 1161 | 0.070 |
Why?
| | Sleep Apnea Syndromes | 1 | 2009 | 90 | 0.070 |
Why?
| | Vaginitis | 1 | 2008 | 2 | 0.070 |
Why?
| | Perception | 1 | 2011 | 378 | 0.070 |
Why?
| | Nuclear Pore | 1 | 2008 | 17 | 0.070 |
Why?
| | Osteoprotegerin | 1 | 2008 | 25 | 0.070 |
Why?
| | Embryo Implantation | 1 | 2008 | 30 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 2056 | 0.070 |
Why?
| | Birth Weight | 2 | 2024 | 520 | 0.070 |
Why?
| | Uterine Prolapse | 1 | 2008 | 15 | 0.070 |
Why?
| | Coronary Disease | 2 | 2012 | 373 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2019 | 1314 | 0.070 |
Why?
| | Androstenedione | 2 | 1999 | 11 | 0.070 |
Why?
| | Infant, Low Birth Weight | 2 | 2019 | 148 | 0.070 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 469 | 0.070 |
Why?
| | Anthropometry | 1 | 2008 | 208 | 0.070 |
Why?
| | Social Class | 1 | 2009 | 273 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2015 | 941 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 655 | 0.070 |
Why?
| | Skin Absorption | 1 | 2007 | 14 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2007 | 330 | 0.060 |
Why?
| | Combined Modality Therapy | 5 | 2021 | 1252 | 0.060 |
Why?
| | Receptors, Steroid | 1 | 2007 | 46 | 0.060 |
Why?
| | Cultural Characteristics | 1 | 2007 | 65 | 0.060 |
Why?
| | Interpersonal Relations | 1 | 2010 | 407 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2011 | 473 | 0.060 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2013 | 661 | 0.060 |
Why?
| | Administration, Topical | 1 | 2007 | 153 | 0.060 |
Why?
| | Asparaginase | 3 | 2001 | 30 | 0.060 |
Why?
| | Research Design | 2 | 2011 | 1123 | 0.060 |
Why?
| | Relaxin | 2 | 1998 | 18 | 0.060 |
Why?
| | Patient Satisfaction | 2 | 2021 | 700 | 0.060 |
Why?
| | Proteins | 3 | 1989 | 1022 | 0.060 |
Why?
| | Age Distribution | 2 | 2004 | 398 | 0.060 |
Why?
| | Gonadal Hormones | 1 | 2005 | 6 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2009 | 524 | 0.060 |
Why?
| | Tissue Donors | 1 | 2009 | 412 | 0.060 |
Why?
| | Phosphorylation | 2 | 2021 | 1781 | 0.060 |
Why?
| | Spouses | 1 | 2007 | 108 | 0.060 |
Why?
| | Entropy | 1 | 2025 | 44 | 0.060 |
Why?
| | Preoptic Area | 1 | 2005 | 8 | 0.060 |
Why?
| | Inhibin-beta Subunits | 1 | 2005 | 6 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2009 | 970 | 0.060 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 78 | 0.060 |
Why?
| | Maternal Age | 2 | 2022 | 131 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Stochastic Processes | 1 | 2025 | 70 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2005 | 35 | 0.060 |
Why?
| | Mathematical Concepts | 1 | 2025 | 36 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 488 | 0.060 |
Why?
| | Blastomeres | 1 | 2004 | 11 | 0.060 |
Why?
| | Iodide Peroxidase | 1 | 2024 | 34 | 0.060 |
Why?
| | Internet | 2 | 2015 | 698 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2014 | 1217 | 0.050 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 263 | 0.050 |
Why?
| | Nuclear Proteins | 3 | 2022 | 749 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2026 | 310 | 0.050 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 272 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 553 | 0.050 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 2 | 2001 | 35 | 0.050 |
Why?
| | Apoptosis | 2 | 2017 | 2519 | 0.050 |
Why?
| | Infusions, Intravenous | 3 | 1994 | 423 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2005 | 175 | 0.050 |
Why?
| | Bone Marrow | 1 | 2005 | 301 | 0.050 |
Why?
| | Central Nervous System | 1 | 2005 | 269 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1292 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2024 | 63 | 0.050 |
Why?
| | Sex Characteristics | 3 | 2019 | 793 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2005 | 259 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 279 | 0.050 |
Why?
| | Elasticity | 2 | 2016 | 193 | 0.050 |
Why?
| | MicroRNAs | 1 | 2009 | 698 | 0.050 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 190 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 42 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 135 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 994 | 0.050 |
Why?
| | Melphalan | 2 | 1999 | 41 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
| | Mass Screening | 1 | 2011 | 1334 | 0.050 |
Why?
| | Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
| | Remission Induction | 4 | 2009 | 306 | 0.050 |
Why?
| | alpha-Amylases | 1 | 2022 | 16 | 0.050 |
Why?
| | Whole-Body Irradiation | 2 | 1999 | 77 | 0.050 |
Why?
| | Thyroid Hormones | 1 | 2022 | 68 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2004 | 425 | 0.040 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2002 | 66 | 0.040 |
Why?
| | Snoring | 1 | 2021 | 18 | 0.040 |
Why?
| | Breast | 1 | 2022 | 158 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 33 | 0.040 |
Why?
| | Computers | 2 | 2000 | 68 | 0.040 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2022 | 88 | 0.040 |
Why?
| | Maternal-Child Nursing | 1 | 2001 | 11 | 0.040 |
Why?
| | Nursing Methodology Research | 1 | 2001 | 45 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2779 | 0.040 |
Why?
| | Executive Function | 1 | 2026 | 463 | 0.040 |
Why?
| | Prevotella | 1 | 2021 | 25 | 0.040 |
Why?
| | Grief | 1 | 2001 | 43 | 0.040 |
Why?
| | X Chromosome | 1 | 2001 | 69 | 0.040 |
Why?
| | Radiography | 2 | 2014 | 846 | 0.040 |
Why?
| | Anger | 1 | 2001 | 62 | 0.040 |
Why?
| | Pulmonary Blastoma | 1 | 2000 | 8 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 133 | 0.040 |
Why?
| | Body Surface Area | 1 | 2020 | 36 | 0.040 |
Why?
| | Canada | 1 | 2022 | 433 | 0.040 |
Why?
| | Insemination | 1 | 2020 | 1 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 254 | 0.040 |
Why?
| | Illinois | 1 | 2020 | 45 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 2000 | 27 | 0.040 |
Why?
| | Paper | 1 | 2000 | 9 | 0.040 |
Why?
| | Blood Volume | 1 | 2020 | 65 | 0.040 |
Why?
| | Gestures | 1 | 2020 | 7 | 0.040 |
Why?
| | Chicago | 1 | 2020 | 66 | 0.040 |
Why?
| | Gestational Age | 1 | 2024 | 970 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2897 | 0.040 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 1999 | 6 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2018 | 3380 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 921 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 515 | 0.040 |
Why?
| | Personal Autonomy | 1 | 2000 | 55 | 0.040 |
Why?
| | Thrombin | 1 | 2000 | 169 | 0.040 |
Why?
| | Observer Variation | 1 | 2000 | 361 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 806 | 0.040 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 1999 | 71 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 55 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2026 | 606 | 0.040 |
Why?
| | Base Sequence | 3 | 2001 | 2199 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 291 | 0.040 |
Why?
| | Gene Deletion | 1 | 2001 | 394 | 0.040 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 2092 | 0.040 |
Why?
| | Triglycerides | 2 | 2017 | 517 | 0.040 |
Why?
| | Chromosome Breakage | 1 | 1999 | 23 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1999 | 41 | 0.040 |
Why?
| | Chromosome Inversion | 1 | 1999 | 19 | 0.040 |
Why?
| | Educational Status | 2 | 2012 | 464 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1984 | 0.040 |
Why?
| | Energy Metabolism | 2 | 2022 | 939 | 0.040 |
Why?
| | Italy | 3 | 2009 | 110 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 347 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 474 | 0.040 |
Why?
| | Hyperthyroidism | 1 | 2018 | 23 | 0.040 |
Why?
| | Diet | 2 | 2023 | 1290 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 453 | 0.040 |
Why?
| | Molecular Sequence Data | 3 | 2001 | 2942 | 0.040 |
Why?
| | Insurance, Health | 1 | 2001 | 299 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 552 | 0.040 |
Why?
| | Genetic Testing | 1 | 2001 | 474 | 0.040 |
Why?
| | Needs Assessment | 1 | 2001 | 392 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 1990 | 203 | 0.030 |
Why?
| | Microinjections | 1 | 1998 | 86 | 0.030 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 6 | 0.030 |
Why?
| | Neurons | 1 | 2007 | 1636 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 137 | 0.030 |
Why?
| | Glucuronates | 1 | 2017 | 5 | 0.030 |
Why?
| | Organ Size | 2 | 2010 | 481 | 0.030 |
Why?
| | Transaminases | 1 | 2017 | 23 | 0.030 |
Why?
| | Conservative Treatment | 1 | 2018 | 41 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2004 | 825 | 0.030 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 11 | 0.030 |
Why?
| | Immunologic Tests | 1 | 1997 | 16 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 404 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 69 | 0.030 |
Why?
| | Disease-Free Survival | 4 | 2001 | 720 | 0.030 |
Why?
| | Pregnancy Tests | 1 | 2017 | 10 | 0.030 |
Why?
| | Biopsy | 1 | 2000 | 1083 | 0.030 |
Why?
| | Vehicle Emissions | 1 | 2017 | 65 | 0.030 |
Why?
| | Public Health | 1 | 2022 | 565 | 0.030 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 320 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 587 | 0.030 |
Why?
| | Biological Assay | 1 | 2017 | 128 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2936 | 0.030 |
Why?
| | Genes | 1 | 1997 | 229 | 0.030 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 39 | 0.030 |
Why?
| | Molecular Weight | 3 | 2013 | 327 | 0.030 |
Why?
| | Thrombosis | 1 | 2000 | 401 | 0.030 |
Why?
| | Transdermal Patch | 1 | 2016 | 15 | 0.030 |
Why?
| | Hepatitis C | 2 | 2011 | 253 | 0.030 |
Why?
| | Hyperprolactinemia | 1 | 2016 | 6 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2001 | 2165 | 0.030 |
Why?
| | Galvanic Skin Response | 1 | 2016 | 26 | 0.030 |
Why?
| | Goiter | 1 | 1996 | 5 | 0.030 |
Why?
| | Genes, Regulator | 1 | 1996 | 36 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2001 | 650 | 0.030 |
Why?
| | Mice | 4 | 2021 | 18378 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 2 | 2008 | 125 | 0.030 |
Why?
| | Serologic Tests | 1 | 2015 | 54 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 557 | 0.030 |
Why?
| | Catheters, Indwelling | 2 | 1993 | 92 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 441 | 0.030 |
Why?
| | Hypothyroidism | 1 | 1996 | 74 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 434 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1996 | 397 | 0.030 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1995 | 36 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1668 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1996 | 165 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 186 | 0.030 |
Why?
| | Alcohol Drinking | 2 | 2012 | 852 | 0.030 |
Why?
| | Genetic Markers | 2 | 2011 | 345 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1999 | 698 | 0.030 |
Why?
| | Cranial Irradiation | 2 | 2009 | 84 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 928 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1029 | 0.030 |
Why?
| | Deafness | 1 | 1996 | 79 | 0.030 |
Why?
| | Certolizumab Pegol | 1 | 2014 | 5 | 0.030 |
Why?
| | Cyclosporine | 1 | 1995 | 266 | 0.030 |
Why?
| | Etanercept | 1 | 2014 | 61 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1504 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1474 | 0.030 |
Why?
| | Vincristine | 3 | 2001 | 135 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 166 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 1563 | 0.030 |
Why?
| | Freezing | 1 | 1994 | 88 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 55 | 0.030 |
Why?
| | Glycerol | 1 | 1994 | 90 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 56 | 0.030 |
Why?
| | Registries | 2 | 2020 | 2238 | 0.030 |
Why?
| | Drug Stability | 1 | 1994 | 165 | 0.030 |
Why?
| | Anions | 1 | 2013 | 31 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 111 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2014 | 166 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 856 | 0.020 |
Why?
| | Medical Records | 1 | 2014 | 185 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2013 | 147 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1997 | 752 | 0.020 |
Why?
| | Electrocardiography | 1 | 2016 | 630 | 0.020 |
Why?
| | Anal Canal | 1 | 1993 | 101 | 0.020 |
Why?
| | Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.020 |
Why?
| | Cell Survival | 2 | 2007 | 1136 | 0.020 |
Why?
| | Air Pollutants | 1 | 2017 | 442 | 0.020 |
Why?
| | Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.020 |
Why?
| | Coffee | 1 | 2012 | 14 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2011 | 38 | 0.020 |
Why?
| | Tea | 1 | 2012 | 17 | 0.020 |
Why?
| | Oogenesis | 1 | 2011 | 19 | 0.020 |
Why?
| | Women | 1 | 2012 | 50 | 0.020 |
Why?
| | Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
| | Rectocele | 1 | 2011 | 4 | 0.020 |
Why?
| | Placentation | 1 | 2011 | 46 | 0.020 |
Why?
| | Mutation, Missense | 2 | 2006 | 346 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 35 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 153 | 0.020 |
Why?
| | Fetal Death | 1 | 2011 | 59 | 0.020 |
Why?
| | Alcoholic Beverages | 1 | 2012 | 30 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 200 | 0.020 |
Why?
| | Ulna Fractures | 1 | 2011 | 16 | 0.020 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2011 | 18 | 0.020 |
Why?
| | Nerve Growth Factor | 1 | 2011 | 34 | 0.020 |
Why?
| | Receptor, trkB | 1 | 2011 | 35 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 208 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2010 | 15 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2011 | 74 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 311 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 168 | 0.020 |
Why?
| | Colon | 1 | 1993 | 306 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 134 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 2 | 0.020 |
Why?
| | Radius Fractures | 1 | 2011 | 69 | 0.020 |
Why?
| | Proinsulin | 1 | 2010 | 52 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 142 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 298 | 0.020 |
Why?
| | Daunorubicin | 2 | 2001 | 25 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2001 | 2887 | 0.020 |
Why?
| | Herpes Zoster | 1 | 2014 | 319 | 0.020 |
Why?
| | Informed Consent | 1 | 2011 | 195 | 0.020 |
Why?
| | Hematology | 1 | 2009 | 21 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 230 | 0.020 |
Why?
| | Survival Rate | 2 | 2009 | 2003 | 0.020 |
Why?
| | Infusion Pumps | 1 | 1989 | 34 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2009 | 7 | 0.020 |
Why?
| | Culture Techniques | 1 | 1989 | 74 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 111 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4658 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 74 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2009 | 74 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 82 | 0.020 |
Why?
| | Prednisone | 2 | 2001 | 232 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 642 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 197 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1993 | 601 | 0.020 |
Why?
| | West Indies | 1 | 2008 | 5 | 0.020 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 5 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 2008 | 14 | 0.020 |
Why?
| | Safety | 1 | 1990 | 357 | 0.020 |
Why?
| | Hyperhidrosis | 1 | 2008 | 6 | 0.020 |
Why?
| | RANK Ligand | 1 | 2008 | 29 | 0.020 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 46 | 0.020 |
Why?
| | Menorrhagia | 1 | 2008 | 22 | 0.020 |
Why?
| | Polysomnography | 1 | 2009 | 242 | 0.020 |
Why?
| | Papio | 1 | 2008 | 92 | 0.020 |
Why?
| | Pelvic Floor | 1 | 2008 | 28 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 927 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1824 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 147 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2531 | 0.020 |
Why?
| | Collagen Type I | 1 | 2008 | 140 | 0.020 |
Why?
| | Isoenzymes | 1 | 2008 | 299 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2007 | 45 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 383 | 0.020 |
Why?
| | Transplantation, Autologous | 2 | 1999 | 284 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 740 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2000 | 2580 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 146 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 173 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2008 | 247 | 0.020 |
Why?
| | Transplantation Conditioning | 2 | 1999 | 186 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2000 | 626 | 0.020 |
Why?
| | Medical Oncology | 1 | 2009 | 328 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 323 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 863 | 0.020 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 63 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1072 | 0.020 |
Why?
| | New York | 1 | 2006 | 131 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 1099 | 0.020 |
Why?
| | Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2010 | 278 | 0.020 |
Why?
| | Body Fluids | 1 | 1986 | 70 | 0.010 |
Why?
| | Microdialysis | 1 | 2005 | 54 | 0.010 |
Why?
| | HIV-1 | 1 | 1991 | 892 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 770 | 0.010 |
Why?
| | Stroke | 1 | 2014 | 1213 | 0.010 |
Why?
| | Neoplasm, Residual | 1 | 2005 | 130 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2007 | 337 | 0.010 |
Why?
| | Communication | 1 | 2011 | 953 | 0.010 |
Why?
| | Urban Population | 1 | 2008 | 491 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3109 | 0.010 |
Why?
| | Demography | 1 | 2005 | 297 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 831 | 0.010 |
Why?
| | Life Change Events | 1 | 2005 | 151 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 289 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 976 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1628 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2005 | 430 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4182 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2001 | 27 | 0.010 |
Why?
| | Interviews as Topic | 1 | 2005 | 868 | 0.010 |
Why?
| | Estrus | 1 | 2001 | 11 | 0.010 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 17 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1183 | 0.010 |
Why?
| | Rest | 1 | 2001 | 128 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2000 | 72 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 143 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 6043 | 0.010 |
Why?
| | Pedigree | 1 | 2001 | 513 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 370 | 0.010 |
Why?
| | Transplants | 1 | 1999 | 39 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 250 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2000 | 326 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1487 | 0.010 |
Why?
| | Consanguinity | 1 | 1999 | 50 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2001 | 270 | 0.010 |
Why?
| | Thioguanine | 1 | 1998 | 18 | 0.010 |
Why?
| | Cytarabine | 1 | 1998 | 65 | 0.010 |
Why?
| | Leucovorin | 1 | 1998 | 87 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1998 | 81 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 288 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1998 | 259 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 1998 | 113 | 0.010 |
Why?
| | Chromosome Aberrations | 1 | 1998 | 164 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 79 | 0.010 |
Why?
| | Doxorubicin | 1 | 1998 | 381 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 537 | 0.010 |
Why?
| | Dexamethasone | 1 | 1998 | 378 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 334 | 0.010 |
Why?
| | Introns | 1 | 1997 | 255 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1997 | 404 | 0.010 |
Why?
| | Risk | 1 | 1998 | 906 | 0.010 |
Why?
| | Exons | 1 | 1997 | 359 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 379 | 0.010 |
Why?
| | Drug Resistance | 1 | 1995 | 153 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1996 | 146 | 0.010 |
Why?
| | Colostomy | 1 | 1993 | 28 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 1114 | 0.010 |
Why?
| | Testis | 1 | 1994 | 166 | 0.010 |
Why?
| | Liver Diseases | 1 | 1996 | 304 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1993 | 159 | 0.010 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1991 | 14 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2000 | 2417 | 0.010 |
Why?
| | Sarcoma, Kaposi | 1 | 1991 | 83 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 605 | 0.010 |
Why?
| | Feedback | 1 | 1990 | 180 | 0.000 |
Why?
| | Equipment Contamination | 1 | 1989 | 71 | 0.000 |
Why?
| | Forearm | 1 | 1989 | 139 | 0.000 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 365 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1989 | 246 | 0.000 |
Why?
| | Organ Culture Techniques | 1 | 1987 | 157 | 0.000 |
Why?
| | Isoelectric Point | 1 | 1986 | 23 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1991 | 758 | 0.000 |
Why?
| | Hemoglobins | 1 | 1986 | 365 | 0.000 |
Why?
| | Bacteria | 1 | 1989 | 888 | 0.000 |
Why?
|
|
Santoro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|